Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml
Semin Thromb Hemost 2025; 51(01): 028-040
DOI: 10.1055/s-0044-1785483
DOI: 10.1055/s-0044-1785483
Review Article
Gene Therapy in Hemophilia A: Achievements, Challenges, and Perspectives
Abstract
Strides in advancements of care of persons with hemophilia include development of long-acting factor replacement therapies, novel substitution and hemostatic rebalancing agents, and most recently approved gene therapy. Several decades of preclinical and clinical trials have led to development of adeno-associated viral (AAV) vector-mediated gene transfer for endogenous production of factor VIII (FVIII) in hemophilia A (HA). Only one gene therapy product for HA (valoctocogene roxaparvovec) has been approved by regulatory authorities. Results of valoctocogene roxaparvovec trial show significant improvement in bleeding rates and use of factor replacement therapy; however, sustainability and duration of response show variability with overall decline in FVIII expression over time. Further challenges include untoward adverse effects involving liver toxicity requiring immunosuppression and development of neutralizing antibodies to AAV vector rendering future doses ineffective. Real-life applicability of gene therapy for HA will require appropriate patient screening, infrastructure setup, long-term monitoring including data collection of patient-reported outcomes and innovative payment schemes. This review article highlights the success and development of HA gene therapy trials, challenges including adverse outcomes and variability of response, and perspectives on approach to gene therapy including shared decision-making and need for future strategies to overcome the several unmet needs.
Publication History
Article published online:
08 April 2024
© 2024. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Berntorp E, Fischer K, Hart DP. et al. Haemophilia. Nat Rev Dis Primers 2021; 7 (01) 45
- 2 Rodriguez-Santana I, DasMahapatra P, Burke T. et al. Differential humanistic and economic burden of mild, moderate and severe haemophilia in European adults: a regression analysis of the CHESS II study. Orphanet J Rare Dis 2022; 17 (01) 148
- 3 Buchbinder D, Ragni MV. What is the role of prophylaxis in the improvement of health-related quality of life of patients with hemophilia?. Hematology (Am Soc Hematol Educ Program) 2013; 2013: 52-55
- 4 Young L, Chen Y, Alvir J, Burke T, Ferri Grazzi E, Winburn I. The impact of bleeding event frequency on health-related quality of life and work productivity outcomes in a European cohort of adults with haemophilia A: insights from the CHESS II study. Orphanet J Rare Dis 2023; 18 (01) 227
- 5 Poon JL, Zhou ZY, Doctor JN. et al. Quality of life in haemophilia A: Hemophilia Utilization Group Study Va (HUGS-Va). Haemophilia 2012; 18 (05) 699-707
- 6 Wiley RE, Khoury CP, Snihur AWK. et al. From the voices of people with haemophilia A and their caregivers: challenges with current treatment, their impact on quality of life and desired improvements in future therapies. Haemophilia 2019; 25 (03) 433-440
- 7 Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care 2016; 22 (Suppl. 05) s126-s133
- 8 Weyand AC, Pipe SW. New therapies for hemophilia. Blood 2019; 133 (05) 389-398
- 9 Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet 2021; 397 (10274): 630-640
- 10 von Drygalski A, Chowdary P, Kulkarni R. et al; XTEND-1 Trial Group. Efanesoctocog Alfa prophylaxis for patients with severe hemophilia A. N Engl J Med 2023; 388 (04) 310-318
- 11 U.S. Food and Drug Administration. FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors. Published October 2018 . Accessed December 6, 2023 at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-emicizumab-kxwh-hemophilia-or-without-factor-viii-inhibitors
- 12 Mahlangu J, Oldenburg J, Paz-Priel I. et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379 (09) 811-822
- 13 Li A, Goodfriend C, Sokol J, Kruse-Jarres R. Patterns and predictors of emicizumab adherence in people with hemophilia. Blood 2019; 134 (Suppl. 01) 2178
- 14 Mahajerin A, Khairnar R, Meyer CS. et al. Real-world persistence with and adherence to emicizumab prophylaxis in persons with hemophilia a: a secondary claims database analysis. Blood 2020; 136 (Suppl. 01) 13
- 15 Oka G, Roussel-Robert V, Levivien C, Lopez I, Pieragostini R. Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy. Haemophilia 2023; 29 (03) 709-715
- 16 Giuffrida G, Nicolosi D, Condorelli A, Markovic U, Di Raimondo F. Use of emicizumab in patients with hemophilia A with and without inhibitors: a single center experience. Blood 2021; 138 (Suppl. 01) 4248
- 17 Gualtierotti R, Pasca S, Ciavarella A. et al. Updates on novel non-replacement drugs for hemophilia. Pharmaceuticals (Basel) 2022; 15 (10) 1183
- 18 Skinner MW, Nugent D, Wilton P. et al. Achieving the unimaginable: health equity in haemophilia. Haemophilia 2020; 26 (01) 17-24
- 19 Thornburg CD, Simmons DH, von Drygalski A. Evaluating gene therapy as a potential paradigm shift in treating severe hemophilia. BioDrugs 2023; 37 (05) 595-606
- 20 Mannucci PM. Hemophilia treatment innovation: 50 years of progress and more to come. J Thromb Haemost 2023; 21 (03) 403-412
- 21 Nathwani AC. Gene therapy for hemophilia. Hematology (Am Soc Hematol Educ Program) 2022; 2022 (01) 569-578
- 22 Leebeek FWG, Miesbach W. Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues. Blood 2021; 138 (11) 923-931
- 23 Samelson-Jones BJ, George LA. Adeno-associated virus gene therapy for hemophilia. Annu Rev Med 2023; 74: 231-247
- 24 Pipe SW, Gonen-Yaacovi G, Segurado OG. Hemophilia A gene therapy: current and next-generation approaches. Expert Opin Biol Ther 2022; 22 (09) 1099-1115
- 25 Gitschier J, Wood WI, Goralka TM. et al. Characterization of the human factor VIII gene. Nature 1984; 312 (5992) 326-330
- 26 Toole JJ, Knopf JL, Wozney JM. et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312 (5992) 342-347
- 27 Eaton DL, Wood WI, Eaton D. et al. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry 1986; 25 (26) 8343-8347
- 28 Kootstra NA, Matsumura R, Verma IM. Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol Ther 2003; 7 (5 Pt 1): 623-631
- 29 Park F, Ohashi K, Kay MA. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 2000; 96 (03) 1173-1176
- 30 Gallo-Penn AM, Shirley PS, Andrews JL. et al. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice. Hum Gene Ther 1999; 10 (11) 1791-1802
- 31 Andrews JL, Shirley PS, Iverson WO. et al. Evaluation of the duration of human factor VIII expression in nonhuman primates after systemic delivery of an adenoviral vector. Hum Gene Ther 2002; 13 (11) 1331-1336
- 32 Brann T, Kayda D, Lyons RM. et al. Adenoviral vector-mediated expression of physiologic levels of human factor VIII in nonhuman primates. Hum Gene Ther 1999; 10 (18) 2999-3011
- 33 Roth DA, Tawa Jr NE, O'Brien JM, Treco DA, Selden RF. Factor VIII Transkaryotic Therapy Study Group. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001; 344 (23) 1735-1742
- 34 Powell JS, Ragni MV, White II GC. et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003; 102 (06) 2038-2045
- 35 Evens H, Chuah MK, VandenDriessche T. Haemophilia gene therapy: From trailblazer to gamechanger. Haemophilia 2018; 24 (Suppl. 06) 50-59
- 36 Chuah MK, Schiedner G, Thorrez L. et al. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 2003; 101 (05) 1734-1743
- 37 Sarkar R, Mucci M, Addya S. et al. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. Hum Gene Ther 2006; 17 (04) 427-439
- 38 Jiang H, Lillicrap D, Patarroyo-White S. et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 2006; 108 (01) 107-115
- 39 Shi Q, Wilcox DA, Fahs SA. et al. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost 2007; 5 (02) 352-361
- 40 Rangarajan S, Walsh L, Lester W. et al. AAV5-Factor VIII gene transfer in severe hemophilia A. N Engl J Med 2017; 377 (26) 2519-2530
- 41 Ozelo MC, Mahlangu J, Pasi KJ. et al; GENEr8-1 Trial Group. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med 2022; 386 (11) 1013-1025
- 42 European Medicines Agency. First gene therapy to treat severe haemophilia A. Published June 24, 2022 . Accessed December 27, 2023 at: https://www.ema.europa.eu/en/news/first-gene-therapy-treat-severe-haemophilia
- 43 U.S. Food and Drug Administration. FDA Approves First Gene Therapy for Adults with Severe Hemophilia A. website. Published June 29, 2023 . Accessed December 27, 2023 at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-adults-severe-hemophilia
- 44 National Bleeding Disorders Foundation. Patient Receives First Hemophilia A Gene Therapy Outside a Clinical Trial. Published January 12, 2024 . Accessed January 15, 2024 at: https://www.hemophilia.org/news/patient-receives-first-hemophilia-a-gene-therapy-outside-a-clinical-trial#:~:text=The%20patient%2C%20an%20adult%20with,and%20Drug%20Administration%20(FDA)
- 45 Mahlangu J, Kaczmarek R, von Drygalski A. et al; GENEr8-1 Trial Group. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N Engl J Med 2023; 388 (08) 694-705
- 46 Pasi KJ, Rangarajan S, Mitchell N. et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med 2020; 382 (01) 29-40
- 47 Mahlangu J, von Drygalski A, Shapiro S. et al. Bleeding, FVIII activity, and safety 3 years after gene transfer with valoctocogene roxaparvovec: results from GENEr8-1. Res Pract Thromb Haemost 2023; 7 (Suppl. 02) 100459
- 48 O'Mahony B, Dunn AL, Leavitt AD. et al. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. J Thromb Haemost 2023; 21 (12) 3450-3462
- 49 Gardner J. . “BioMarin Reports Cancer Case in Hemophilia Gene Therapy Trial.” BioPharma Dive. Published September 13, 2022 . Accessed February 28, 2024 at: www.biopharmadive.com/news/biomarin-reports-cancer-case-in-hemophilia-gene-therapy-trial/631648/
- 50 Symington E, Rangarajan S, Lester W. et al. Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment. Haemophilia 2024; 30 (02) 320-330
- 51 Schmidt M, Foster GR, Coppens M. et al. Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B. Blood Adv 2023; 7 (17) 4966-4969
- 52 European Association for Hemophilia and Allied Disorders Haemophilia (EAHAD) Gene Therapy Trials Database. EAHAD website. Database last updated February 2, 2024 . Accessed February 4, 2024 at: https://eahadgtd.mdsas.com/
- 53 Leavitt AD, Konkle BA, Stine KC. et al. Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study. Blood 2024; 143 (09) 796-806
- 54 Rasul E, Hallock R, Hellmann M. et al. Gene therapy in Hemophilia: a transformational patient experience. J Patient Exp 2023; 10: 23 743735231193573
- 55 NBDF. National Bleeding Disorders Foundation (NBDF) Medical and Scientific Advisory Council Document 282 - MASAC Recommendations on Hemophilia Treatment Center Preparedness for Delivering Gene Therapy for Hemophilia. Published October 27, 2023 . Accessed January 15, 2024 at: https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-282-masac-recommendations-on-hemophilia-treatment-center-preparedness-for-delivering-gene-therapy-for-hemophilia
- 56 Krumb E, Lambert C, Hermans C. Patient selection for hemophilia gene therapy: real-life data from a single center. Res Pract Thromb Haemost 2021; 5 (03) 390-394
- 57 Fletcher S, Jenner K, Holland M, Khair K. Expectation and loss when gene therapy for haemophilia is not an option: an exigency sub-study. Haemophilia 2023; 29 (03) 776-783
- 58 U.S. Food and Drug Administration. ROCTAVIAN (valoctocogene roxaparvovec-rvox) prescribing information. Revised June 2023 . Accessed December 27, 2023 at: https://www.fda.gov/media/169937/download
- 59 Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4 (01) 59-72
- 60 Hay CR, DiMichele DM. International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119 (06) 1335-1344
- 61 Malec L, Van Damme A, Chan AKC. et al. Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study. Blood 2023; 141 (16) 1982-1989
- 62 Carcao M, Shapiro A, Hwang N. et al. Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: a follow-up retrospective analysis. Haemophilia 2021; 27 (01) 19-25
- 63 Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia 2015; 21 (03) 310-319
- 64 Klamroth R, Hayes G, Andreeva T. et al. Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A. Hum Gene Ther 2022; 33 (7-8): 432-441
- 65 U.S. Food and Drug Administration. AAV5 DetectCDx – P190033. Updated September 22, 2023 . Accessed January 17, 2024 at: https://www.fda.gov/medical-devices/recently-approved-devices/aav5-detectcdx-p190033
- 66 ARUP Laboratories. Approval of AAV5 DetectCDx™ Provides Access to Companion Diagnostic for Hemophilia A Gene Therapy. Published November 10, 2023 . Accessed January 17, 2024 at: www.aruplab.com https://www.aruplab.com/news/11-10-2023/eu-approval-aav5-detectcdxtm-provides-access
- 67 Pipe SW, Leebeek FWG, Recht M. et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med 2023; 388 (08) 706-718
- 68 Ragni MV, Majerus E, Fong S. et al. Valoctocogene roxaparvovec gene transfer in participants with HIV. Blood Adv 2023; 7 (08) 1525-1530
- 69 Khair K, Steadman L, Chaplin S, Holland M, Jenner K, Fletcher S. Parental perspectives on gene therapy for children with haemophilia: The Exigency study. Haemophilia 2021; 27 (01) 120-128
- 70 Pipe SW, Reddy KR, Chowdary P. Gene therapy: practical aspects of implementation. Haemophilia 2022; 28 (Suppl. 04) 44-52
- 71 Miesbach W, Foster GR, Peyvandi F. Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists. J Thromb Haemost 2023; 21 (02) 200-203
- 72 Miesbach W, Pasi KJ, Pipe SW. et al. Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre's readiness in United States and EU. Haemophilia 2021; 27 (04) 511-514
- 73 Miesbach W, Chowdary P, Coppens M. et al. Delivery of AAV-based gene therapy through haemophilia centres-a need for re-evaluation of infrastructure and comprehensive care: a joint publication of EAHAD and EHC. Haemophilia 2021; 27 (06) 967-973
- 74 Pipe S, Douglas K, Hwang N, Young G, Patel P, Fogarty P. Delivery of gene therapy in haemophilia treatment centres in the United States: practical aspects of preparedness and implementation. Haemophilia 2023; 29 (06) 1430-1441
- 75 Kay MA. AAV vectors and tumorigenicity. Nat Biotechnol 2007; 25 (10) 1111-1113
- 76 Konkle BA, Peyvandi F, Coffin D, Naccache M, Youttananukorn T, Pierce GF. WFH Gene Therapy Registry Scientific Advisory Board. Landmark endorsement of a global registry: The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), publicly endorses World Federation of Hemophilia Gene Therapy Registry as global standard. Haemophilia 2024; 30 (01) 232-235
- 77 Shah J, Kim H, Sivamurthy K, Monahan PE, Fries M. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B. Curr Med Res Opin 2023; 39 (02) 227-237
- 78 Arruda VR. Why is AAV FVIII gene therapy not approved by the US Food and Drug Administration yet?. Blood Adv 2021; 5 (20) 4313
- 79 Batty P, Lillicrap D. Gene therapy for hemophilia: current status and laboratory consequences. Int J Lab Hematol 2021; 43 (Suppl. 01) 117-123
- 80 Rind D, Walton S, Agboola F. et al. Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value. Final report. Institute for Clinical and Economic Review. Published November 20, 2020 . Accessed January 24, 2023 at: https://icer.org/wp-content/uploads/2020/10/ICER_Hemophilia-A_Final-Report_112020.pdf
- 81 Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Adv 2018; 2 (14) 1792-1798
- 82 Cook K, Forbes SP, Adamski K, Ma JJ, Chawla A, Garrison Jr LP. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A. J Med Econ 2020; 23 (05) 501-512
- 83 Ten Ham RMT, Walker SM, Soares MO. et al. Modeling benefits, costs, and affordability of a novel gene therapy in hemophilia A. [published correction appears in Hemasphere. 2022 Feb 15;6(3):e698] HemaSphere 2022; 6 (02) e679
- 84 Astermark J, Buckner TW, Frenzel L. et al. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis. Haemophilia 2023; 29 (04) 1087-1094
- 85 Skinner MW, Dolan G, Eichler H, O'Mahony B. International Haemophilia Access Strategy Council. A preliminary application of a haemophilia value framework to emerging therapies in haemophilia. Haemophilia 2022; 28 (Suppl. 02) 9-18
- 86 World Federation of Hemophilia. World Federation of Hemophilia Shared Decision Making Tool. Accessed January 24, 2024 at: https://sdm.wfh.org/
- 87 Limjoco J, Thornburg CD. Gene therapy for hemophilia A: a mixed methods study of patient preferences and shared decision-making. Patient Prefer Adherence 2023; 17: 1093-1105
- 88 Fletcher S, Jenner K, Pembroke L, Holland M, Khair K. The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study. Orphanet J Rare Dis 2022; 17 (01) 155
- 89 Iorio A, Skinner MW, Clearfield E. et al; coreHEM panel. Core outcome set for gene therapy in haemophilia: results of the coreHEM multistakeholder project. Haemophilia 2018; 24 (04) e167-e172
- 90 Fletcher S, Jenner K, Holland M, Chaplin S, Khair K. An exploration of why men with severe haemophilia might not want gene therapy: The exigency study. Haemophilia 2021; 27 (05) 760-768
- 91 Bolous NS, Bhatt N, Bhakta N, Neufeld EJ, Davidoff AM, Reiss UM. Gene therapy and hemophilia: where do we go from here?. J Blood Med 2022; 13: 559-580
- 92 van Overbeeke E, Michelsen S, Toumi M. et al. Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discov Today 2021; 26 (02) 399-415
- 93 Reiss UM, Mahlangu J, Ohmori T, Ozelo MC, Srivastava A, Zhang L. Haemophilia gene therapy-Update on new country initiatives. Haemophilia 2022; 28 (Suppl. 04) 61-67
- 94 Doering CB, Denning G, Shields JE. et al. Preclinical development of a hematopoietic stem and progenitor cell bioengineered factor VIII lentiviral vector gene therapy for hemophilia A. Hum Gene Ther 2018; 29 (10) 1183-1201
- 95 Singh G, Mohanashankar AM, Velayudhan SR. et al. Assessment of Transduction of CD34+ human hematopoietic stem cells from patients with severe hemophilia-A with lentiviral vector carrying a high expression FVIII Transgene (CD68–ET3-LV). Blood 2023; 142 (Suppl. 01) 481
- 96 Chen H, Shi M, Gilam A. et al. Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII. Sci Rep 2019; 9 (01) 16838
- 97 Zhang JP, Cheng XX, Zhao M. et al. Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse. Genome Biol 2019; 20 (01) 276
- 98 Luo S, Li Z, Dai X. et al. CRISPR/Cas9-mediated in vivo genetic correction in a mouse model of hemophilia A. Front Cell Dev Biol 2021; 9: 672564
- 99 Segurado OG, Jiang R, Pipe SW. Challenges and opportunities when transitioning from in vivo gene replacement to in vivo CRISPR/Cas9 therapies - a spotlight on hemophilia. Expert Opin Biol Ther 2022; 22 (09) 1091-1098
- 100 De Wolf D, Singh K, Chuah MK, VandenDriessche T. Hemophilia gene therapy: the end of the beginning?. Hum Gene Ther 2023; 34 (17-18): 782-792
- 101 U.S. National Library of Medicine. Home - ClinicalTrials.gov. Clinicaltrials.gov. Accessed February 4, 2024 at: https://clinicaltrials.gov/